Clinical Characteristics of 126 Cytogenetically Studied Patients With Different Subtypes of BBCL
| Histopathological Lymphoma Subtype According to: . | ||||||
|---|---|---|---|---|---|---|
| Kiel Classification . | cb Lymphoma . | ib Lymphoma . | BL . | Centrocytoid-cb Lymphoma . | Other BBCL‡ Lymphoma . | All . |
| REAL Classification . | Diffuse Large Cell Lymphoma . | BL . | bMCL Variant† . | Other High-Grade BCL‡ . | ||
| Clinical Data | ||||||
| Total | 68 (54.0%) | 28 (22.2%) | 11 (8.7%) | 11 (8.7%) | 8 (6.4%) | 126 (100%) |
| Gender (male:female) | 28:40 | 11:17 | 7:4 | 7:4 | 5:3 | 58:68 |
| Age (yr), median (range) | 61 (17-88) | 67 (21-94) | 44 (16-72) | 63 (60-71) | 48 (28-68) | 60 (19-94) |
| International Prognostic Index | ||||||
| Age >60 yr | 36 (53%) | 19 (68%) | 2 (18%) | 8 (73%) | 2 (25%) | 67 (53%) |
| Karnofsky Index ≤70% | 7 (10%) | 2 (7%) | 1 (9%) | 2 (18%) | 1 (12.5%) | 13 (10%) |
| Serum-LDH >240 U/I | 36 (53%) | 18 (64%) | 4 (36%) | 7 (63%) | 5 (63%) | 70 (56%) |
| Ann Arbor Stage III/IV | 39 (57%) | 19 (68%) | 5 (46%) | 10 (91%) | 7 (88%) | 80 (64%) |
| No. of E-sites* ≥2 | 6 (9%) | 5 (18%) | 2 (18%) | 3 (27%) | 1 (13%) | 17 (14%) |
| Median survival (mo) (95% CI) | 68.9 (27-112) | 16.3 (10-22) | 38.7 (44-112) | 14.4 (8-24) | 15.2 (12-33) | 24.2 (16-38) |
| Histopathological Lymphoma Subtype According to: . | ||||||
|---|---|---|---|---|---|---|
| Kiel Classification . | cb Lymphoma . | ib Lymphoma . | BL . | Centrocytoid-cb Lymphoma . | Other BBCL‡ Lymphoma . | All . |
| REAL Classification . | Diffuse Large Cell Lymphoma . | BL . | bMCL Variant† . | Other High-Grade BCL‡ . | ||
| Clinical Data | ||||||
| Total | 68 (54.0%) | 28 (22.2%) | 11 (8.7%) | 11 (8.7%) | 8 (6.4%) | 126 (100%) |
| Gender (male:female) | 28:40 | 11:17 | 7:4 | 7:4 | 5:3 | 58:68 |
| Age (yr), median (range) | 61 (17-88) | 67 (21-94) | 44 (16-72) | 63 (60-71) | 48 (28-68) | 60 (19-94) |
| International Prognostic Index | ||||||
| Age >60 yr | 36 (53%) | 19 (68%) | 2 (18%) | 8 (73%) | 2 (25%) | 67 (53%) |
| Karnofsky Index ≤70% | 7 (10%) | 2 (7%) | 1 (9%) | 2 (18%) | 1 (12.5%) | 13 (10%) |
| Serum-LDH >240 U/I | 36 (53%) | 18 (64%) | 4 (36%) | 7 (63%) | 5 (63%) | 70 (56%) |
| Ann Arbor Stage III/IV | 39 (57%) | 19 (68%) | 5 (46%) | 10 (91%) | 7 (88%) | 80 (64%) |
| No. of E-sites* ≥2 | 6 (9%) | 5 (18%) | 2 (18%) | 3 (27%) | 1 (13%) | 17 (14%) |
| Median survival (mo) (95% CI) | 68.9 (27-112) | 16.3 (10-22) | 38.7 (44-112) | 14.4 (8-24) | 15.2 (12-33) | 24.2 (16-38) |